Brief: Tonix, Mass General Partner on Phase 2 Trial of TNX-1500 to Prevent Kidney Transplant Organ Rejection
04/11/2025 12:31
Nov 4 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O: TONIX PHARMACEUTICALS ANNOUNCES COLLABORATION WITH MASSACHUSETTS GENERAL HOSPITAL TO ADVANCE PHASE 2 CLINICAL TRIAL OF DIMERIC FC-MODIFIED ANTI-CD40L MAB, TNX-1500, TO PREVENT KIDNEY TRANSPLANT ORGAN REJECTION Source text: ID:nGNX4D6fXK Further company coverage: TNXP.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tonix Pharmaceuticals Holding
See all newsBrief: Tonix Pharmaceuticals Says Dr. Reddy's Files ANDA With Paragraph IV Patent Certification For Generic Tonmya
Brief: Tonix Pharmaceuticals Announces Second Major Managed Medicare Payer Agreement For Tonmya®
Tonix Pharmaceuticals Holding Corp. reports results for the quarter ended June 30 - Earnings Summary
Tonix Q2 revenue rises sharply on TONMYA launch
Tonix Pharmaceuticals Holding Corp. expected to post a loss of $2.70 a share - Earnings Preview